MeiraGTx Holdings plc (NASDAQ:MGTX) Shares Bought by Privium Fund Management B.V.

Privium Fund Management B.V. grew its holdings in MeiraGTx Holdings plc (NASDAQ:MGTX) by 5.2% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 225,078 shares of the company’s stock after purchasing an additional 11,118 shares during the quarter. Privium Fund Management B.V. owned approximately 0.29% of MeiraGTx worth $1,371,000 at the end of the most recent quarter.

Other hedge funds have also modified their holdings of the company. Janney Montgomery Scott LLC acquired a new stake in MeiraGTx during the 4th quarter valued at $459,000. Barclays PLC lifted its holdings in shares of MeiraGTx by 107.1% during the 3rd quarter. Barclays PLC now owns 147,827 shares of the company’s stock worth $618,000 after acquiring an additional 76,437 shares during the period. State Street Corp boosted its holdings in shares of MeiraGTx by 0.9% in the 3rd quarter. State Street Corp now owns 574,727 shares of the company’s stock valued at $2,397,000 after purchasing an additional 5,251 shares during the last quarter. Garden State Investment Advisory Services LLC acquired a new position in MeiraGTx in the third quarter valued at $1,636,000. Finally, JPMorgan Chase & Co. lifted its stake in shares of MeiraGTx by 1.2% in the 3rd quarter. JPMorgan Chase & Co. now owns 342,667 shares of the company’s stock valued at $1,429,000 after purchasing an additional 4,186 shares in the last quarter. 67.48% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several equities analysts recently weighed in on MGTX shares. Royal Bank of Canada lifted their target price on shares of MeiraGTx from $11.00 to $13.00 and gave the company an “outperform” rating in a report on Monday. Chardan Capital reissued a “buy” rating and issued a $36.00 price target on shares of MeiraGTx in a report on Monday, February 24th.

Insider Activity at MeiraGTx

In other MeiraGTx news, CFO Richard Giroux sold 24,000 shares of the business’s stock in a transaction on Tuesday, January 21st. The shares were sold at an average price of $6.29, for a total transaction of $150,960.00. Following the completion of the sale, the chief financial officer now owns 849,947 shares in the company, valued at $5,346,166.63. The trade was a 2.75 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO Alexandria Forbes sold 35,839 shares of the firm’s stock in a transaction dated Tuesday, January 7th. The stock was sold at an average price of $6.47, for a total transaction of $231,878.33. Following the completion of the transaction, the chief executive officer now owns 1,395,102 shares in the company, valued at approximately $9,026,309.94. The trade was a 2.50 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 8.40% of the company’s stock.

MeiraGTx Price Performance

Shares of MGTX stock opened at $7.50 on Wednesday. The firm has a fifty day moving average of $6.59 and a two-hundred day moving average of $5.88. The firm has a market cap of $586.15 million, a P/E ratio of -6.20, a P/E/G ratio of 0.37 and a beta of 1.23. MeiraGTx Holdings plc has a 1-year low of $3.85 and a 1-year high of $8.75. The company has a debt-to-equity ratio of 0.86, a current ratio of 2.34 and a quick ratio of 2.34.

MeiraGTx (NASDAQ:MGTX) last posted its quarterly earnings results on Thursday, March 13th. The company reported ($0.50) EPS for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.02). MeiraGTx had a negative return on equity of 146.38% and a negative net margin of 633.05%. The firm had revenue of $21.39 million during the quarter, compared to analyst estimates of $1.50 million. As a group, research analysts anticipate that MeiraGTx Holdings plc will post -1.48 earnings per share for the current fiscal year.

MeiraGTx Company Profile

MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases, neurodegenerative diseases, and xerostomia.